Merit Medical Systems (NASDAQ:MMSI) Given New $95.00 Price Target at JPMorgan Chase & Co.

Merit Medical Systems (NASDAQ:MMSI) had its price target increased by JPMorgan Chase & Co. from $77.00 to $95.00 in a research report report published on Friday,Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the medical instruments supplier’s stock.

Other equities research analysts have also recently issued research reports about the stock. Citigroup reissued an “outperform” rating on shares of Merit Medical Systems in a research report on Monday, April 20th. Wells Fargo & Company raised their price target on shares of Merit Medical Systems from $74.00 to $83.00 and gave the stock an “equal weight” rating in a research report on Friday. Barrington Research set a $114.00 price objective on shares of Merit Medical Systems in a research note on Friday. Compass Point set a $107.00 price objective on shares of Merit Medical Systems in a report on Monday, April 20th. Finally, Weiss Ratings lowered shares of Merit Medical Systems from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, May 8th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Merit Medical Systems presently has an average rating of “Moderate Buy” and a consensus price target of $100.30.

Merit Medical Systems Stock Performance

NASDAQ:MMSI opened at $85.01 on Friday. The stock has a 50 day simple moving average of $69.87 and a 200 day simple moving average of $71.78. The stock has a market cap of $5.07 billion, a P/E ratio of 35.13, a PEG ratio of 2.59 and a beta of 0.52. Merit Medical Systems has a 1-year low of $59.74 and a 1-year high of $94.75. The company has a current ratio of 5.08, a quick ratio of 3.46 and a debt-to-equity ratio of 0.45.

Merit Medical Systems (NASDAQ:MMSI) last issued its quarterly earnings data on Thursday, July 30th. The medical instruments supplier reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $0.96 by $0.23. The firm had revenue of $418.84 million for the quarter, compared to analyst estimates of $405.25 million. Merit Medical Systems had a return on equity of 13.97% and a net margin of 9.22%.The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.01 EPS. Merit Medical Systems has set its FY 2026 guidance at 4.250-4.350 EPS. Research analysts anticipate that Merit Medical Systems will post 3.62 earnings per share for the current year.

Insider Buying and Selling at Merit Medical Systems

In related news, insider Brian G. Lloyd purchased 2,000 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The stock was acquired at an average price of $62.62 per share, with a total value of $125,240.00. Following the completion of the purchase, the insider directly owned 2,000 shares in the company, valued at $125,240. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Lynne N. Ward sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $62.61, for a total transaction of $313,050.00. Following the sale, the director directly owned 7,809 shares of the company’s stock, valued at $488,921.49. This represents a 39.04% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Merit Medical Systems

Large investors have recently bought and sold shares of the company. Gradient Investments LLC bought a new position in Merit Medical Systems in the 2nd quarter valued at about $1,657,000. GAMMA Investing LLC lifted its holdings in shares of Merit Medical Systems by 235.4% during the 2nd quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier’s stock worth $225,000 after acquiring an additional 2,281 shares during the period. Harbor Investment Advisory LLC bought a new stake in shares of Merit Medical Systems during the 2nd quarter worth approximately $50,000. Central Pacific Bank Trust Division increased its stake in Merit Medical Systems by 13.9% in the second quarter. Central Pacific Bank Trust Division now owns 3,107 shares of the medical instruments supplier’s stock valued at $215,000 after acquiring an additional 380 shares during the last quarter. Finally, Epiq Partners LLC bought a new position in Merit Medical Systems in the second quarter valued at approximately $208,000. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Key Merit Medical Systems News

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q2 results exceeded expectations: Merit reported revenue of $418.8 million, up 9.5% year over year and above the $405.3 million consensus estimate. Non-GAAP EPS rose 18% to $1.19, beating estimates of $0.96; GAAP operating margin also improved to 14.4% from 12.3%. Merit Medical Reports Second Quarter 2026 Results and Updates Full-Year 2026 Guidance
• Positive Sentiment: 2026 guidance was raised: Management now expects full-year adjusted EPS of $4.25-$4.35, above the $3.98 analyst consensus. Broad-based product growth, revenue gains and expanding margins supported the improved outlook. MMSI Q2 Earnings, Revenues Beat Estimates; 2026 Guidance Raised
• Positive Sentiment: Analyst targets moved higher: Needham raised its target to $101 and maintained a Buy rating; BTIG lifted its target to $105 and maintained Buy; and JPMorgan raised its target to $95 with an Overweight rating. These revisions indicate increased confidence in Merit’s growth and earnings trajectory. Analysts Increase Forecasts After Strong Q2 Results
• Neutral Sentiment: Analyst opinion remains mixed: Wells Fargo raised its target to $83 but retained an Equal Weight rating, leaving its target below the stock’s recent trading level. Wells Fargo Raises Merit Medical Price Target
• Negative Sentiment: Cash generation weakened: Year-to-date operating cash flow fell 11% to $110.0 million, while free cash flow declined 14% to $76.6 million, a potential concern despite the strong earnings performance. Merit Medical Second Quarter Results

About Merit Medical Systems

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.